ASH 2009: Oral panobinostat and bortezomib for relapsed multiple myeloma

Share :
Published: 1 Mar 2010
Views: 10752
Rating:
Save
Prof Jesus Fernando San-Miguel - University Hospital of Salamanca, Spain
Prof San-Miguel discusses the phase IB, multi-centre, open-label dose-escalation study of oral
pPanobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma.

Click here to see Prof San-Miguel talking at EHA 2010 about the progression in myeloma survival rates.